Dr Reddy's Lab faces Betapharm writedowns

24 Feb 2009

Hyderabad-based Dr Reddy's Laboratories (DRL) may have to write down the intangible value of major products in its German subsidiary Betapharm during the current quarter, which may squeeze the Indian firm's earnings for FY09.

 

DRL has already made two major provisions towards Betapharm impairments of over Rs 400 crore. However, the spokesman did not confirm the exact quantum of the provisions made so far.

 

The unimpaired goodwill in respect of the major products marketed by Betapharm is currently estimated at about 150 million euros. Thus the provision for impairments and pricing pressure in the German market are likely to impact the earnings of the company in the current financial year.

crackcrack
Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

4406.20 -47.10 (-1.06%) Mar 02, 16:21
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 614.40
Dr. Reddys Lab 4406.20
Lupin 1054.60
Piramal Enterprises 1918.00
Cadila Healthcare 440.95
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback